| Orilissa (elagolix) / AbbVie |
CTR20223250: Human bioequivalence study of oxalagris tablets |
|
|
| Not yet recruiting | 1 | 81 | China | 1. Chinese Generic Name: Elagolix Tablets; English Generic Name: Elagolix Tablets; Brand Name: NA; 1. Chinese Generic Name: Elagolix Tablets; English Generic Name: Elagolix Tablets; Brand Name: ORILISSA? | Fu'an Pharmaceutical Group Ningbo Tianheng Pharmaceutical Co., Ltd. | Indications: For the treatment of moderate to severe pain associated with endometriosis. | | | | |
NCT01403038: An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females |
|
|
| Completed | 1 | 216 | US | Elagolix, ABT-620, elagolix sodium, elagolix | AbbVie (prior sponsor, Abbott), Neurocrine Biosciences | Folliculogenesis | 10/12 | 11/12 | | |
NCT04445025: Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis |
|
|
| Completed | 1 | 30 | US | Elagolix 200 MG, Leuprolide Acetate 3.75 MG/ML, Lab work | Colorado Center for Reproductive Medicine, AbbVie | Infertility, Endometriosis | 09/24 | 12/24 | | |
NCT03746535: Cardiovascular Disease Risk in Women With Endometriosis |
|
|
| Recruiting | 1 | 40 | US | Elagolix | Yale University, National Heart, Lung, and Blood Institute (NHLBI) | Endometriosis | 12/25 | 12/26 | | |
